U2AF1 and pancreatic neoplasm: Since lower U2AF1 expression predicted poorer prognosis, we knocked down U2AF1 in BxPC-3 and AsPC-1 pancreatic cancer cells using shRNA, which significantly reduced both the mRNA and protein levels of U2AF1 (Figure 2D,E), and then measured the expression of CD44V3.